Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

BetterLife Pharma

BETRFOTCQB

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$0.0756

At close: Jan 2, 1:21 PM EDT

$0.1000

0.0232.28%

After Hours: Jul 5, 9:19 AM EDT

BetterLife Pharma (BETRF) Forecast

News

Earnings BetterLife Pharma (BETRF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest news for BetterLife Pharma (OTC:BETRF) Stock

BetterLife Pharma Stock (OTC: BETRF)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, April 17, 2024

Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Lara Goldstein

Saturday, March 16, 2024

Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
Lara Goldstein

Tuesday, July 04, 2023

Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
Lara Goldstein

Wednesday, June 28, 2023

BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives
Lara Goldstein

Tuesday, June 13, 2023

Psyched: Dubai Psychedelics Event, Key Receptor Discovered, Drew Barrymore, Oprah's Guest, Swiss MDMA & More
Lara Goldstein

Friday, June 09, 2023

BetterLife's Non-Hallucinogenic LSD's Clinical Studies, Braxia's Psychedelic Treatments Continue
Lara Goldstein

Monday, March 13, 2023

Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
Lara Goldstein

Thursday, March 09, 2023

Mood Disorders Could Get An Alternative Treatment With This Next-Gen, Non-Hallucinogenic Psychedelic
Lara Goldstein

Thursday, January 26, 2023

BetterLife Engages Canadian Healthcare Investment Firm, Aims For Clinical Trial Programs
Lara Goldstein

Tuesday, September 27, 2022

Psychedelics Companies And IPs: An Extended Patent Application To Protect Multiple LSD Derivatives
Lara Goldstein

Wednesday, August 24, 2022

Study Reveals LSD May Boost Memory And Performance Without Those Hallucinating Side Effects
Lara Goldstein

Wednesday, July 06, 2022

BetterLife's Preclinical Studies Of BETR-001 For Depression Gets Additional Sponsorship By Mitacs
Lara Goldstein

Monday, November 15, 2021

EXCLUSIVE: Can Non-Hallucinogenic Psychedelic Compounds Treat Mental Health Conditions? This Company Thinks So!
Jacinta Sherris - Sponsored

Monday, October 18, 2021

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Natan Ponieman

Wednesday, October 13, 2021

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Natan Ponieman

Wednesday, August 11, 2021

What Do You Really Know About Psychedelics And Psychedelics Stocks?
Jeff Siegel

Tuesday, April 06, 2021

Psyched: MindMed's 2020 Financials, Psychedelics ETF Rebalancing, Country's First Psychedelics Masters Degree
Natan Ponieman

Tuesday, March 30, 2021

Why Would Anyone Invest In The Psychedelics Medicine Market?   
Jeff Siegel

Monday, February 08, 2021

Cannabis Stock Gainers And Losers From February 8, 2021
Jose Rodrigo Safdiye

Tuesday, January 05, 2021

Why The Psychedelics Market Is NOT Cannabis 2.0
Jeff Siegel

Monday, December 14, 2020

Psyched: Canada Allows Psilocybin Use For Healthcare Pros, UK Begins DMT Trials, Cybin To Purchase Adelia
Natan Ponieman

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved